Most Popular
-
1
Yoon pushes for Xi’s visit to firm up ties with China
-
2
Esports legend Faker seeks to lead Korean surge at Asian Games
-
3
Incheon Airport passenger traffic to recover during Chuseok holiday
-
4
[Hello Hangeul] The making of Korean language textbooks featuring BTS
![[Hello Hangeul] The making of Korean language textbooks featuring BTS](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2023/09/24/20230924000121_0.jpg&u=)
-
5
Seoul prepares for first major military parade in ten years
-
6
Opposition leader Lee attends arrest warrant hearing at Seoul court
-
7
Korea trade volume sees sharp drop among OECD members
-
8
[Korea Beyond Korea] Early Koreanists 'on verge of extinction overseas'
![[Korea Beyond Korea] Early Koreanists 'on verge of extinction overseas'](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2023/09/25/20230925000556_0.jpg&u=20230925160918)
-
9
Young swimmer enjoys self-fulfilling prophecy in gold medal-winning race
-
10
Chief justice seat at top court left vacant amid Assembly chaos
![[Hello Hangeul] The making of Korean language textbooks featuring BTS](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2023/09/24/20230924000121_0.jpg&u=)
![[Korea Beyond Korea] Early Koreanists 'on verge of extinction overseas'](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2023/09/25/20230925000556_0.jpg&u=20230925160918)
Samsung Bioepis wins approval to sell biosimilar in South Korea
By Jo He-rimPublished : Sept. 20, 2017 - 20:54
Samsung Biologics Co. said Wednesday its affiliate Samsung Bioepis Co. won a nod from South Korea‘s drug agency to sell its biosimilar dubbed SB5.
Through the approval granted by the Ministry of Food and Drug Safety, Samsung Biologics said in a regulatory filing that the biosimilar is ready for sale in the country.
The SB5 is a biosimilar of Humira released by U.S.-based AbbVie Inc., used for the treatment of various diseases including Crohn’s disease and rheumatoid arthritis.
A biosimilar is a copy of a medicine developed after the patents for the original drug have expired.
Samsung Biologics said the detailed launch schedule of the biosimilar will be fixed later to reflect the patent expiration date of Humira.
Samsung Bioepis is a joint venture between Samsung Biologics and U.S. Biogen Inc.
![[KH Explains] Lotte goes all out to secure cash amid lackluster earnings](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=652&simg=/content/image/2023/09/26/20230926000485_0.jpg&u=)
![[Herald Interview] As a wanderer, Yoshitomo Nara does not confine himself to art](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=652&simg=/content/image/2023/09/25/20230925000732_0.jpg&u=20230926110820)
